Literature DB >> 3553434

Blood-brain barrier permeability during Cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases.

D A Bakker, S K Ludwin.   

Abstract

Blood vessels in the superior cerebellar peduncles were studied in Cuprizone-fed mice for leakage of proteins into the parenchyma. The status of the blood-brain barrier was determined at various stages of demyelination both by tracer methods using horseradish peroxidase and immunochemically using antisera to extravasated serum proteins and was compared to three positive and negative control conditions. The results showed no evidence of significant protein leakage into the subendothelial basement membrane or extravascular space in Cuprizone mice, during the development of demyelination. The apparent lack of damage to the blood-brain barrier found in Cuprizone animals as compared to the blood-brain barrier alterations previously reported for immune-mediated demyelinating diseases, confirms the theory that these alterations are not a non-specific association of any demyelinating process, but are of primary pathogenetic importance in immune-mediated demyelination.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3553434     DOI: 10.1016/0022-510x(87)90055-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  31 in total

1.  MHC class II exacerbates demyelination in vivo independently of T cells.

Authors:  Meenaxi M Hiremath; Vivian S Chen; Kinuko Suzuki; Jenny P Y Ting; Glenn K Matsushima
Journal:  J Neuroimmunol       Date:  2008-10-15       Impact factor: 3.478

2.  Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia.

Authors:  Maria Karamita; Christopher Barnum; Wiebke Möbius; Malú G Tansey; David E Szymkowski; Hans Lassmann; Lesley Probert
Journal:  JCI Insight       Date:  2017-04-20

3.  CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model.

Authors:  Sarah A Ingersoll; Carol B Martin; Scott R Barnum; Brian K Martin
Journal:  Mol Immunol       Date:  2010-09-01       Impact factor: 4.407

4.  Beneficial effects of minocycline on cuprizone induced cortical demyelination.

Authors:  Thomas Skripuletz; Elvira Miller; Darius Moharregh-Khiabani; Alexander Blank; Refik Pul; Viktoria Gudi; Corinna Trebst; Martin Stangel
Journal:  Neurochem Res       Date:  2010-06-11       Impact factor: 3.996

Review 5.  Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination.

Authors:  Jens Watzlawik; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2010-03       Impact factor: 4.618

6.  Yokukansan Reduces Cuprizone-Induced Demyelination in the Corpus Callosum Through Anti-inflammatory Effects on Microglia.

Authors:  Taichi Nomura; Yoshio Bando; Hua You; Tatsuhide Tanaka; Shigetaka Yoshida
Journal:  Neurochem Res       Date:  2017-09-19       Impact factor: 3.996

7.  Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent.

Authors:  Thomas Skripuletz; Maren Lindner; Alexandra Kotsiari; Niklas Garde; Jantje Fokuhl; Franziska Linsmeier; Corinna Trebst; Martin Stangel
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

8.  Microglial recruitment, activation, and proliferation in response to primary demyelination.

Authors:  Leah T Remington; Alicia A Babcock; Simone P Zehntner; Trevor Owens
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

9.  Comparative prion disease gene expression profiling using the prion disease mimetic, cuprizone.

Authors:  Laura R Moody; Allen J Herbst; Han Sang Yoo; Joshua P Vanderloo; Judd M Aiken
Journal:  Prion       Date:  2009-04-19       Impact factor: 3.931

10.  Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination.

Authors:  S Komoly; L D Hudson; H D Webster; C A Bondy
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.